Analyst Ratings For Allergan plc (NYSE:AGN)
Today, Royal Bank of Canada set its price target on Allergan plc (NYSE:AGN) to $220.00 per share.
There are 18 Buy Ratings, 4 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Allergan plc (NYSE:AGN) is Buy with a consensus target price of $211.8535 per share, a potential 36.46% upside.
Some recent analyst ratings include
- 11/12/2018-Allergan plc (NYSE:AGN) has coverage initiated with a Outperform rating and $220.00 price target
- 10/31/2018-Allergan plc (NYSE:AGN) had its Buy rating reiterated by Wells Fargo & Co
- 10/8/2018-Allergan plc (NYSE:AGN) has coverage initiated with a Buy ➝ Buy rating
- On 11/16/2018 Matthew M. Walsh, CFO, bought 1,000 with an average share price of $157.00 per share and the total transaction amounting to $157,000.00.
- On 9/6/2018 Christopher J. Coughlin, Director, bought 10,000 with an average share price of $190.64 per share and the total transaction amounting to $1,906,400.00.
- On 8/30/2018 Joseph H. Boccuzi, Director, bought 900 with an average share price of $190.59 per share and the total transaction amounting to $171,531.00.
- On 5/17/2018 William Meury, EVP, sold 24,425 with an average share price of $154.59 per share and the total transaction amounting to $3,775,860.75.
- On 3/15/2018 Maria Teresa Hilado, Insider, bought 895 with an average share price of $167.39 per share and the total transaction amounting to $149,814.05.
- On 3/8/2018 Brent L. Saunders, CEO, bought 3,300 with an average share price of $152.53 per share and the total transaction amounting to $503,349.00.
- On 3/8/2018 Matthew M. Walsh, CFO, bought 1,000 with an average share price of $153.96 per share and the total transaction amounting to $153,960.00.
About Allergan plc (NYSE:AGN)
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories. It also provides breast implants and tissue expanders; RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis; ocular implants; and Kybella, a non-surgical treatment for submental fullness. In addition, the company develops therapies for non-alcoholic steatohepatitis and other liver diseases; treatments for neurodegenerative disorders, including Alzheimer's disease; small molecule therapeutics that target inflammatory and fibrotic diseases; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; strategic alliance and option agreement with Editas Medicine, Inc.; and licensing agreements with Assembly Biosciences, Inc. MedImmune, and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Recent Trading Activity for Allergan plc (NYSE:AGN)
Shares of Allergan plc closed the previous trading session at 155.24 0.00 0.00% with 155.99 shares trading hands.